Chairman And Chief Executive Officer
Current
Sernova (Sva.To)
CEO of transformative Regenerative Medicine Company
Aug 2024 - Present
AeroLeads people directory · profile
Jonathan Rigby Email & Phone Number
Dynamic and Driven CEO, Active Chairman, Enabling Board Member, Creative Strategist, Problem Resolver, Objective Realizer, Value Multiplier and Respectful Colleague.
at
IM Therapeutics
2 work emails found
@zogenix.com
3 phones found area 925, 510, and 858
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Dynamic and Driven CEO, Active Chairman, Enabling Board Member, Creative Strategist, Problem Resolver, Objective Realizer, Value Multiplier and Respectful Colleague.
Location
Cambridge, Massachusetts, United States
Who is Jonathan Rigby? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Jonathan Rigby is listed as Dynamic and Driven CEO, Active Chairman, Enabling Board Member, Creative Strategist, Problem Resolver, Objective Realizer, Value Multiplier and Respectful Colleague. at IM Therapeutics, based in Cambridge, Massachusetts, United States. AeroLeads shows a work email signal at zogenix.com, phone signal with area code 925, 510, 858, and a matched LinkedIn profile for Jonathan Rigby.
Jonathan Rigby previously worked as Chairman and Chief Executive Officer at Sernova (Sva.To) and Executive Chairman Board of Directors at Sernova (Sva.To). Jonathan Rigby holds Biological Sciences (Honors) from The University Of Sheffield.
Company email context
Email format at IM Therapeutics
This section adds company-level context without repeating Jonathan Rigby's masked contact details.
{first_initial}{last}@zogenix.com
89% confidence
AeroLeads found 2 current-domain work email signals for Jonathan Rigby. Compare company email patterns before reaching out.
Profile bio
About Jonathan Rigby
Jonathan Rigby is an accomplished executive with a proven track record in the pharmaceutical, biotech, and drug delivery industry across the United States, Europe, and Israel. Serving as CEO, President, Board Member, and Chairman. Having privately and publicly financed three bio / pharma companiesJonathan excels in leading strategic initiatives, building great teams that execute, problem-solving, and challenging processes to drive drug product innovation, shareholder value, and employee satisfaction.With extensive experience founding and leading three specialty pharma and biotech companies, Jonathan has earned a reputation for overcoming challenging obstacles and successfully advancing drug products from development through launch. His expertise spans strategic foresight, exemplary leadership, corporate growth, capital raising, including four IPO’s and two public to public company mergers. His track record of problem-solving, assumption challenging, outcome optimization, convincing communication, and positive culture building has led to extensive value creation.In his recent role as President, Board Member and Group CEO of Revolo Biotherapeutics, Jonathan led the transformative change of a pre-clinical company to a clinical-stage immunology-focused Biotech company in a time and cost-efficient fashion. Under his leadership, the company secured significant private financing, established a strong management team, and advanced drug products for autoimmune and inflammatory allergic diseases through four clinical trials, inc two Phase 2a trials with positive data.As Chairman and Chief Business Officer of BIOS acquisition company, Jonathan co-led a successful Nasdaq IPO and spearheaded the merger agreement with a U.S company focused on cardiology. Jonathan's entrepreneurial spirit is evident in his founding and growth of SteadyMed Therapeutics, Inc., where he developed a drug product to treat Pulmonary Hypertension, raised substantial capital from investors such as Deerfield, Federated and Orbimed leading to an IPO. After leading a successful IP challenge Jonathan orchestrated a public-to-public company acquisition of SteadyMed by United Therapeutics (Nasdaq: UTHR).Prior to SteadyMed Jonathan co-founded Zogenix Inc with tier 1 investors, played a key role in its Nasdaq IPO. Zogenix was acquired by UCB in a multibillion-dollar transaction.
Listed skills include Pharmaceutical Industry, Biotechnology, Medical Devices, Commercialization, and 36 others.
Current workplace
Jonathan Rigby's current company
Company context helps verify the profile and gives searchers a useful next step.
15 roles · 36 years
Jonathan Rigby work experience
A career timeline built from the work history available for this profile.
Executive Chairman Board Of Directors
Current
Sernova (Sva.To)
May 2024 - Present
Member Board Of Directors, Chairman Governance Committee
Current
Oncolytics Biotech Inc. (Nasdaq: Oncy)
Sep 2022 - Present
Chairman And Cbo
Current
Bios Acquisition Corporation
Jul 2021 - Present
Board Member
CurrentIMT is the first company to target the root cause of autoimmunity with therapeutic design directed at HLA variants known to confer high disease risk. The Company platform builds drug molecules for specific blockade of an HLA protein in a given autoimmune disease as a novel paradigm in drug development.
Oct 2020 - Present
President, Group Ceo And Board Member
Revolo Biotherapeutics, based in the U.S. and U.K., is a clinical stage biotech company developing novel, first-in-class, drug therapies for resetting the immune system, for autoimmune and allergic disease. Its immune-resetting therapies have demonstrated unique efficacy and safety in preclinical and human studies without suppressing the immune system..
Jan 2020 - Feb 2024
Board Member
Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).Thermalin’s formulations of these new molecules enable new delivery devices.
Jul 2020 - Aug 2021
President & Ceo Steadymed; A United Therapeutics Company (Nasdaq; Uthr)
United Therapeutics
After the successful sale of SteadyMed Inc. (Nasdaq; STDY) to United Therapeutics in August 2018, agreed to remain to complete the integration of the U.S. U.K. and Israel based technical, clinical, finance, manufacturing and regulatory operations and select personnel into United, RTP, NC. and see through to completion the filing of the NDA for SteadyMeds.
Sep 2018 - Jan 2020
Chairman Of The Board
Collplant Biotechnologies
CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, medical aesthetics, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets.
Dec 2018 - Dec 2019
Member Board Of Directors, Audit Committee And Chairman Of The Nominating And Governance Committee
Xeris Pharmaceuticals (Nasdaq: Xers)
XERIS is a specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including management of Hypoglycemia and Acute Repetitive Seizures (ARS).
Mar 2016 - Apr 2019
President, Ceo And Board Member Steadymed (Nasdaq; Stdy)
Strategic leadership and capital raising for a growing, publicly traded, multinational, Specialty Pharmaceutical Company focused on proprietary product development in the fields of Pulmonary Arterial Hypertension (PAH) & At Home Patient Analgesia (AHPA), as well as the development and licensing of large volume parenteral drug delivery systems.SteadyMed.
Jan 2011 - Aug 2018
Co Founder & Vp Business Development
Zogenix Inc, (Nasdaq; Zgnx)
Co founded the company, raised >$250M equity financing, launched drug delivery enabled CNS pharmaceutical product in US and EU and IPO 2010. Zogenix acquired by UCB Pharma for $2B.
Aug 2006 - Dec 2010
Vice President Business Development & Licensing
Aradigm Corporation (Nasdaq: Ardm)
Led BD efforts culminating in multiple large pharma collaborations. In licensed controlled release technology to develop inhaled treprostinil, licensed to United Therapeutics for the treatment of PAH. In licensed controlled release technology leading to development of inhaled ciprofloxacin for non CF Bronchiectasis. Initiated and led acquisition of UK.
2002 - 2006
~4 yrs
Head Business Development And Uk Sales & Marketing
Profile Therapeutics / Phillips Medical
Led BD efforts on drug delivery technology licensing from the UK. Licensed inhalation technology for treatment of Pulmonary Arterial Hypertension for global branded product.Led sales and marketing for inhalation equipment across all UK.
Jul 1995 - Jun 2002
Various
Merck, Bristol Myers Squibb
Various Sales and Marketing leadership roles in the pharmaceutical industry
1990 - 1995
~5 yrs
4 education records
Jonathan Rigby education
Biological Sciences (Honors)
The University Of Sheffield
Master Of Business Administration - Mba
University Of Portsmouth
Master Of Business Administration - Mba
University Of Portsmouth
Mba, Business Adminstration
University Of Portsmouth, Uk
FAQ
Frequently asked questions about Jonathan Rigby
Quick answers generated from the profile data available on this page.
What company does Jonathan Rigby work for?
Jonathan Rigby works for IM Therapeutics.
What is Jonathan Rigby's role at IM Therapeutics?
Jonathan Rigby is listed as Dynamic and Driven CEO, Active Chairman, Enabling Board Member, Creative Strategist, Problem Resolver, Objective Realizer, Value Multiplier and Respectful Colleague. at IM Therapeutics.
What is Jonathan Rigby's email address?
AeroLeads has found 2 work email signals at @zogenix.com for Jonathan Rigby at IM Therapeutics.
What is Jonathan Rigby's phone number?
AeroLeads has found 3 phone signal(s) with area code 925, 510, 858 for Jonathan Rigby at IM Therapeutics.
Where is Jonathan Rigby based?
Jonathan Rigby is based in Cambridge, Massachusetts, United States while working with IM Therapeutics.
What companies has Jonathan Rigby worked for?
Jonathan Rigby has worked for Sernova (Sva.To), Oncolytics Biotech Inc. (Nasdaq: Oncy), Bios Acquisition Corporation, Im Therapeutics, and Revolo Biotherapeutics.
How can I contact Jonathan Rigby?
You can use AeroLeads to view verified contact signals for Jonathan Rigby at IM Therapeutics, including work email, phone, and LinkedIn data when available.
What schools did Jonathan Rigby attend?
Jonathan Rigby holds Biological Sciences (Honors) from The University Of Sheffield.
What skills is Jonathan Rigby known for?
Jonathan Rigby is listed with skills including Pharmaceutical Industry, Biotechnology, Medical Devices, Commercialization, Drug Delivery, Start Ups, Lifesciences, and Technology Transfer.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial